The mechanism of action of thrombin inhibitors

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Bates, Shannon M ^a   Weitz, Jeffrey I ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FIBRIN; THROMBIN RECEPTOR; THROMBOCYTE FACTOR 4;

BLOOD; BLOOD CLOTTING; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; FIBRINOLYTIC THERAPY; HUMAN; METABOLISM; METHODOLOGY; REVIEW; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; BLOOD COAGULATION; CORONARY THROMBOSIS; FIBRIN; HUMANS; PLATELET ACTIVATION; PLATELET FACTOR 4; RECEPTORS, THROMBIN; THROMBOLYTIC THERAPY;

EID: 0034573085     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
2. Fuster V, Badimon J, Chesebro JH, et al. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996;26(Suppl 4):269-284.
3. Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin's structure. Thromb Res 1993;69:1-58.
4. Hogg PJ, Block PE. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost 1997;77:424-433.
5. Becker DL, Fredenburgh JC, Stafford AR, et al. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 1999;274:6226-6233.
6. Hogg PJ, Jackson CM, Labanowski JK, et al. Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen. J Biol Chem 1996;271:26088-26095.
7. Wilner GD, Danitz MP, Mudd MS, et al. Selective immobilization of a-thrombin by surface-bound fibrin. J Lab Clin Med 1981;97:403-411.
8. Berliner LJ, Sugawara Y, Fenton JW II. Human a-thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region. Biochemistry 1985;27:7005-7009.
9. Kaminski M, McDonagh J. Inhibited thrombins. Interactions with fibrinogen and fibrin. Biochem J 1987;242:881-887.
10. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, et al. Structure of the hirulog -1 complexes of α-thrombin. J Mol Biol 1991;221:1379-1393.
11. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990;249:277-280.
12. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14784.
13. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997;272:14477-14482.
14. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci 1981;78:2249-2252.
15. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982;257:7944-7947.
16. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochem Biophys Acta 1979;571:333-342.
17. Fulcher CA, Gardiner JE, Griffen JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984;64:486-489.
18. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
19. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643.
20. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin in protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
21. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-552.
22. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci 1989;86:3619-3623.
23. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by heparin-antithrombin complex. J Clin Invest 1983;71:1383-1391.
24. Pieters J, Willems G, Hemker HC, et al. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988;263:15313-15318.
25. Rosenberg RD, Bauer KA. The heparin-antithrombin system. A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzamn EW (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd edition. Philadelphia: Lippincott Co., 1994: pp. 837-860.
26. Weitz JI. Low-molecular-weight-heparins. N Engl J Med 1997;337:688-698.
27. Lane DA. Heparin binding and neutralizing proteins. In: Lane DA, Lindahl U (eds). Heparin: Chemical and Biological Properties and Clinical Applications. Boca Raton, FL: CRC Press, 1989: pp. 363-391.
28. de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu: Evidence of the importance of the multimerization degree of vWF. Thromb Haemost 1993;69:436-440.
29. Young E, Cosmi B, Weitz J, et al. Comparison of the non-specific binding of unfractionated heparin and low-molecular-weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993;70:625-730.
30. Young E, Wells P, Holloway S, et al. Ex vivo and in vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304.
31. Markwardt F. Past, present, and future of hirudin. Haemostasis 1991;21(Suppl 1):11-26.
32. Rydel TJ, Ravichaandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990;249:277-280.
33. Stringer KA, Lindenfeld J. Hirudins: Antithrombin anticoagulants. Ann Pharmacotherapy 1992;26:267-280.
34. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101.
35. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-163.
36. Witting JL, Bourdon P, Brezniak DV, et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992;283:737-743.
37. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994;33:14807-14814.
38. Bivalirudin draft package insert, July 26,2000.
39. Weitz JI, Hirsh J. New antithrombotic agents. Chest 1998;114(Suppl):715S-727S.
40. Lyle TA. Small-molecule inhibitors of thrombin. Perspect Drug Discov Design 1993;1:453-460.
41. Tapparelli G, Metternich R, Ehrhardt C, et al. Synthetic low-molecular-weight thrombin inhibitors: Molecular design and pharmacological profile. Trends Pharmacol Sci 1993;14:366-376.
42. Das J, Kimball SD. Thrombin active site inhibitors. Bioorg Med Chem 1995;3:999-1007.
43. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4,-tetrahydro-8-quinilinyl)sulfonyl]-1- arginy;)'-2-piperidinecarboxylic acid. Biochemistry 1984;23:85-90.
44. Texas Biotech Press release: see website at http:// www.medscape.com/reuters/prof/2000/07/07.03/20000703rg lt001.html
45. Hilpert K, Ackerman J, Banner DW, et al. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994;37:3889-3901.
46. Teger Nilsson AC, Bylund R, Gustafson D, et al. In vitro effects of inogatran, a selective low-molecular-weight thrombin inhibitors. Thromb Res 1997;85:133-145.
47. Gustafson D, Antonson T, Bylund R, et al. Effect of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-118.
48. Shuman RT, Rothenberger RB, Campbell CS, et al. Highly selective tripeptide thrombin inhibitors. J Med Chem 1993;36:314-319.
49. Mehdi S. Synthetic and naturally occurring protease inhibitors containing an electrophillic carbonyl group. Bioorg Chem 1993;21:249-259.
50. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364-372.
51. Antman EM, for the TIMI 9A investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9Aa Trial. Circulation 1994;90:1624-1630.
52. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
53. Neuhause KL, von Essen R, Tebbe U, et al. Safety observation from the pilot phase of the randomized r-hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischeer Krankenausärzte (ALKK). Circulation 1994;90:1638-1642.
54. Bittl JA, Strony J, Brinker JA, et al., for the Hirulog Angioplasty Study investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
55. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study investigators. Am Heart J 1995;130:658-665.
56. White HD, Aylward PE, Frey MJ, et al., for the Hirulog Early Reperfusion/Occlusion (HERO) Trial investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
57. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049-2053.
58. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
59. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI 9B) trial. Circulation 1996;94:911-921.
60. Serruys PW, Herrmann JP, Simon P, et al., for the HELVETICA investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.